Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2017 03:11 ET | Source: Prima BioMed Ltd

Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDA

SYDNEY, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce that it held a Pre-Investigational New Drug Application (pre-IND)...
November 08, 2017 17:45 ET | Source: Prima BioMed Ltd

New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

SYDNEY, Australia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial...
October 31, 2017 19:15 ET | Source: Prima BioMed Ltd

Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017

SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer,...
October 19, 2017 23:22 ET | Source: Prima BioMed Ltd

Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017

SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer,...
October 17, 2017 00:36 ET | Source: Prima BioMed Ltd

IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

SYDNEY, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that new data investigating the use of eftilagimod alpha (IMP321), the Company’s...
September 08, 2017 01:24 ET | Source: Prima BioMed Ltd

Prima Secures Japanese Patent Grant for IMP731 Antibody

SYDNEY, Australia, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of Japanese patent no. 6177735 entitled “Cytotoxic...
September 05, 2017 03:54 ET | Source: Prima BioMed Ltd

Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease

SYDNEY, Australia, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of patent number 6169734 entitled “Use of Recombinant...
August 30, 2017 06:06 ET | Source: Prima BioMed Ltd

Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project

SYDNEY, Australia, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) announces that the Australian Research Council (ARC) has awarded Prima and...
August 20, 2017 20:06 ET | Source: Prima BioMed Ltd

Prima BioMed Appoints Non-Executive Director to the Board

SYDNEY, Australia, Aug. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that Grant Chamberlain will join the Board as a Non-Executive...
August 15, 2017 22:00 ET | Source: Prima BioMed Ltd

Prima BioMed Receives A $1.3 Million Tax Refund From French Government

SYDNEY, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) is pleased to announce that it has received a €876,635 (A$1,306,266) cash...